Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I–II breast cancers
BACKGROUND: Reductions in the dose intensity (DI) of adjuvant anthracycline-based chemotherapy in early stage breast cancer are frequently required due to treatment toxicity or poor tolerance, but the implications of a minimal reduction in DI on clinical outcome remain uncertain. PATIENTS AND METHOD...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234069/ https://www.ncbi.nlm.nih.gov/pubmed/22275960 http://dx.doi.org/10.3332/eCMS.2008.63 |
_version_ | 1782218466837659648 |
---|---|
author | Tinker, AV Speers, C Barnett, J Olivotto, IA Chia, S |
author_facet | Tinker, AV Speers, C Barnett, J Olivotto, IA Chia, S |
author_sort | Tinker, AV |
collection | PubMed |
description | BACKGROUND: Reductions in the dose intensity (DI) of adjuvant anthracycline-based chemotherapy in early stage breast cancer are frequently required due to treatment toxicity or poor tolerance, but the implications of a minimal reduction in DI on clinical outcome remain uncertain. PATIENTS AND METHODS: Women with stage I–II breast cancer treated with adjuvant adriamycin and cyclophosphamide (AC) from 1990–95 were identified in a provincial breast cancer database. Cases were classified into four cohorts: (1) all cycles delivered at full dose and on time; (2) one single dose reduction or dose delay; (3) >1 dose reduction or dose delay; (4) <2 cycles of chemotherapy delivered. RESULTS: 484 eligible cases were identified (cohort (1): n = 268; (2): n= 88; (3): n= 89; (4) n= 39). Slight imbalances in lymph node status (p=0.05) and adjuvant hormonal therapy (p=0.05) were observed between the cohorts. Fifty-five per cent (267/484) of the patients had node-positive disease and 33% (158/484) were ER+. 45% of cases had a reduction in DI. With a median follow-up of 9.6 years, there were no significant differences in relapse-free survival (p=0.94), breast cancer-specific survival (p=0.87) or overall survival (p=0.86) between the four cohorts. Outcomes were independent of hormone receptor status. CONCLUSIONS: Although toxicity related reductions in the DI of adjuvant AC chemotherapy for early stage breast cancer are common, they did not appear to significantly impact on clinical outcomes in this population-based cohort of women with stage I–II breast cancers. |
format | Online Article Text |
id | pubmed-3234069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-32340692012-01-24 Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I–II breast cancers Tinker, AV Speers, C Barnett, J Olivotto, IA Chia, S Ecancermedicalscience Research Article BACKGROUND: Reductions in the dose intensity (DI) of adjuvant anthracycline-based chemotherapy in early stage breast cancer are frequently required due to treatment toxicity or poor tolerance, but the implications of a minimal reduction in DI on clinical outcome remain uncertain. PATIENTS AND METHODS: Women with stage I–II breast cancer treated with adjuvant adriamycin and cyclophosphamide (AC) from 1990–95 were identified in a provincial breast cancer database. Cases were classified into four cohorts: (1) all cycles delivered at full dose and on time; (2) one single dose reduction or dose delay; (3) >1 dose reduction or dose delay; (4) <2 cycles of chemotherapy delivered. RESULTS: 484 eligible cases were identified (cohort (1): n = 268; (2): n= 88; (3): n= 89; (4) n= 39). Slight imbalances in lymph node status (p=0.05) and adjuvant hormonal therapy (p=0.05) were observed between the cohorts. Fifty-five per cent (267/484) of the patients had node-positive disease and 33% (158/484) were ER+. 45% of cases had a reduction in DI. With a median follow-up of 9.6 years, there were no significant differences in relapse-free survival (p=0.94), breast cancer-specific survival (p=0.87) or overall survival (p=0.86) between the four cohorts. Outcomes were independent of hormone receptor status. CONCLUSIONS: Although toxicity related reductions in the DI of adjuvant AC chemotherapy for early stage breast cancer are common, they did not appear to significantly impact on clinical outcomes in this population-based cohort of women with stage I–II breast cancers. Cancer Intelligence 2008-07-08 /pmc/articles/PMC3234069/ /pubmed/22275960 http://dx.doi.org/10.3332/eCMS.2008.63 Text en Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Tinker, AV Speers, C Barnett, J Olivotto, IA Chia, S Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I–II breast cancers |
title | Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I–II breast cancers |
title_full | Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I–II breast cancers |
title_fullStr | Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I–II breast cancers |
title_full_unstemmed | Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I–II breast cancers |
title_short | Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I–II breast cancers |
title_sort | impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage i–ii breast cancers |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234069/ https://www.ncbi.nlm.nih.gov/pubmed/22275960 http://dx.doi.org/10.3332/eCMS.2008.63 |
work_keys_str_mv | AT tinkerav impactofareduceddoseintensityofadjuvantanthracyclinebasedchemotherapyinapopulationbasedcohortofstageiiibreastcancers AT speersc impactofareduceddoseintensityofadjuvantanthracyclinebasedchemotherapyinapopulationbasedcohortofstageiiibreastcancers AT barnettj impactofareduceddoseintensityofadjuvantanthracyclinebasedchemotherapyinapopulationbasedcohortofstageiiibreastcancers AT olivottoia impactofareduceddoseintensityofadjuvantanthracyclinebasedchemotherapyinapopulationbasedcohortofstageiiibreastcancers AT chias impactofareduceddoseintensityofadjuvantanthracyclinebasedchemotherapyinapopulationbasedcohortofstageiiibreastcancers |